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Pediatric Acute Lymphoblastic Leukemia Patients and Potential 
Risk for Vincristine Side Effects with Concomitant Fluconazole
Reyna Ramirez, James Ford DO, Chittal Raulji MD, Caleb Cave MD, Robin High MBA MA, and Jill Beck MD
University of Nebraska Medical Center, Omaha, NE; Children’s Hospital & Medical Center, Omaha, NE
o Pediatric Acute Lymphoblastic Leukemia (ALL) treatment involves 
the administration of vincristine (VCR), an anticancer drug that inhibits 
cell replication during mitosis.[1]
o There are various side effects of vincristine therapy, including neuropathy 
(sensory, motor, autonomic), electrolyte abnormalities (namely, 
hyponatremia from SIADH), and GI symptoms.
o Patients undergoing ALL treatment are at high risk for opportunistic 
infections, including invasive fungal infection (IFI).[2]
o To prevent IFIs, some patients receive antifungal prophylaxis. Our 
institution primarily prescribes fluconazole.[3]
o Fluconazole inhibits metabolism of vincristine by acting as a substrate 
and inhibitor of CYP3A4.[6-8] Because of their inhibition of vincristine 
metabolism, azoles can potentiate some of the side effects of 
vincristine.[4,5,6]
o We analyzed whether the use of fluconazole prophylaxis impacts 
vincristine’s side effects during induction therapy.
Method
o We conducted a retrospective chart review of all pediatric (age 0-18 
years) patients diagnosed with ALL at Children’s Hospital and Medical 
Center in Omaha, Nebraska from July 2013-May 2021.
o We collected data on demographics, disease characteristics, and 
treatment protocol.
o Patients were divided into two groups based on whether or not they 
received fluconazole.
o Incidence of fungal infection, rate and grade of peripheral neuropathy, 
and prescription for gabapentin (treatment for peripheral neuropathy) 
were collected for both groups.
o Sodium nadir during induction was noted for both groups, as an 
indication for development of SIADH.
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Table 1. Patient’s Characteristics by Fluconazole Exposure
Table 3. Comparison of Neuropathy Grade with the Age of Diagnostic 
Variables Fluconazole 
No 























Table 2. Sodium Levels and Peripheral Neuropathy According to 
Fluconazole Exposure 
Conclusion and Future Directions
o We did not find a statistically significant difference that the use of 
concomitant fluconazole with vincristine increased the risk of peripheral 
neuropathy or hyponatremia.
o Our results help to clarify that the concomitant use of fluconazole with 
vincristine for ALL treatment is safe and does not increase the risk of side 
effects
o Further investigation needs to be done to explore the association 
between age at diagnosis and increased hyponatremia and neuropathy 
using multivariate analysis. 
o Our data did not find a correlation between fluconazole use and increased 
incidence of peripheral neuropathy (p value = 0.28)
o Interestingly, fluconazole use did not increase the rate of hyponatremia 
but is associated with less hyponatremia (p value = <0.001)
o Lack of fluconazole prophylaxis did not increase the rate of 
fungal infection in this study. In fact, the two cases of reported fungal 
infections were noted in patients receiving fluconazole prophylaxis.
o Patients' ethnicity did not influence occurrence of neuropathy (OR 1.33, p 
= 0.43) or hyponatremia (OR = 0.0584, p = 0.14)
o As the age at diagnosis increased, the presence of hyponatremia 
increased compared to normal. Incidence of higher-grade neuropathy also 
increased as the age at diagnosis increased.
